Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.

Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin X, Li G, Liu Y, Li X, Sun W, Zhang H, Li X, Zhou Z, Yan M, Wang X, Sha W, Ji J, Cheng X, Zhou Z, Xu J, Du X.

PLoS One. 2013 Nov 14;8(11):e80290. doi: 10.1371/journal.pone.0080290. eCollection 2013.

2.

Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.

Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A.

Am J Surg Pathol. 2012 Apr;36(4):577-82. doi: 10.1097/PAS.0b013e318244adbb.

PMID:
22314190
3.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
4.

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J.

Gastric Cancer. 2015 Jul;18(3):476-84. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20.

5.

Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.

Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, Balakan O, Eser EP, Ozturk SC, Ozkan M, Oksuzoglu B, Sevinc A, Demir N, Harputluoglu H, Yalcin B, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO).

J Gastrointest Surg. 2015 Sep;19(9):1565-71. doi: 10.1007/s11605-015-2888-y. Epub 2015 Jul 16.

PMID:
26179664
6.

Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.

Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, Tsuda H.

Virchows Arch. 2014 Aug;465(2):145-54. doi: 10.1007/s00428-014-1597-3. Epub 2014 Jun 3.

PMID:
24889042
7.

Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.

Koopman T, Louwen M, Hage M, Smits MM, Imholz AL.

Am J Clin Pathol. 2015 Feb;143(2):257-64. doi: 10.1309/AJCPCX69HGDDGYCQ.

PMID:
25596252
8.

Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.

Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, Han SW, Oh DY, Lee HJ, Kim TY, Kim WH, Yang HK, Bang YJ.

Diagn Mol Pathol. 2011 Jun;20(2):94-100. doi: 10.1097/PDM.0b013e3181fc02b7.

PMID:
21532492
9.

[Dual-color silver-enhanced in-situ hybridization for determination of HER2 gene amplification in gastric carcinoma].

Fan D, Li Y, Ran W, Yu W, Li H.

Zhonghua Bing Li Xue Za Zhi. 2014 Jan;43(1):4-7. Chinese.

PMID:
24713241
10.

HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.

Cappellesso R, Fassan M, Hanspeter E, Bornschein J, d'Amore ES, Cuorvo LV, Mazzoleni G, Barbareschi M, Pizzi M, Guzzardo V, Malfertheiner P, Micev M, Guido M, Giacomelli L, Tsukanov VV, Zagonel V, Nitti D, Rugge M.

Hum Pathol. 2015 May;46(5):665-72. doi: 10.1016/j.humpath.2015.02.007. Epub 2015 Feb 27.

PMID:
25800719
11.
12.

Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.

Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A.

Hum Pathol. 2014 May;45(5):970-5. doi: 10.1016/j.humpath.2013.12.010. Epub 2014 Jan 8.

PMID:
24656529
13.

Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.

Fassan M, Ludwig K, Pizzi M, Castoro C, Guzzardo V, Balistreri M, Zaninotto G, Ruol A, Giacomelli L, Ancona E, Rugge M.

Hum Pathol. 2012 Aug;43(8):1206-12. doi: 10.1016/j.humpath.2011.09.004. Epub 2012 Jan 2.

PMID:
22217477
14.

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, Buyukberber S.

Jpn J Clin Oncol. 2015 May;45(5):416-21. doi: 10.1093/jjco/hyv020. Epub 2015 Mar 2.

PMID:
25732909
15.

HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.

Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB, Schaeffer DF.

Arch Pathol Lab Med. 2014 Nov;138(11):1495-502. doi: 10.5858/arpa.2013-0604-OA.

PMID:
25357111
16.

Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.

Jeung J, Patel R, Vila L, Wakefield D, Liu C.

Arch Pathol Lab Med. 2012 Jun;136(6):610-7. doi: 10.5858/arpa.2011-0371-OA.

17.
19.

A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.

Cho J, Jeong J, Sung J, Sung CO, Kim KM, Park CK, Choi MG, Sohn TS, Bae JM, Kim S.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S477-84. doi: 10.1245/s10434-012-2818-0. Epub 2012 Dec 30.

PMID:
23274580
20.

HER2 testing in gastric cancer: a practical approach.

Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G.

Mod Pathol. 2012 May;25(5):637-50. doi: 10.1038/modpathol.2011.198. Epub 2012 Jan 6.

Supplemental Content

Support Center